Literature DB >> 21890694

High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents.

Junyi Ma1, Liang Guo, Steve J Fiene, Blake D Anson, James A Thomson, Timothy J Kamp, Kyle L Kolaja, Bradley J Swanson, Craig T January.   

Abstract

Human-induced pluripotent stem cells (hiPSCs) can differentiate into functional cardiomyocytes; however, the electrophysiological properties of hiPSC-derived cardiomyocytes have yet to be fully characterized. We performed detailed electrophysiological characterization of highly pure hiPSC-derived cardiomyocytes. Action potentials (APs) were recorded from spontaneously beating cardiomyocytes using a perforated patch method and had atrial-, nodal-, and ventricular-like properties. Ventricular-like APs were more common and had maximum diastolic potentials close to those of human cardiac myocytes, AP durations were within the range of the normal human electrocardiographic QT interval, and APs showed expected sensitivity to multiple drugs (tetrodotoxin, nifedipine, and E4031). Early afterdepolarizations (EADs) were induced with E4031 and were bradycardia dependent, and EAD peak voltage varied inversely with the EAD take-off potential. Gating properties of seven ionic currents were studied including sodium (I(Na)), L-type calcium (I(Ca)), hyperpolarization-activated pacemaker (I(f)), transient outward potassium (I(to)), inward rectifier potassium (I(K1)), and the rapidly and slowly activating components of delayed rectifier potassium (I(Kr) and I(Ks), respectively) current. The high purity and large cell numbers also enabled automated patch-clamp analysis. We conclude that these hiPSC-derived cardiomyocytes have ionic currents and channel gating properties underlying their APs and EADs that are quantitatively similar to those reported for human cardiac myocytes. These hiPSC-derived cardiomyocytes have the added advantage that they can be used in high-throughput assays, and they have the potential to impact multiple areas of cardiovascular research and therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890694      PMCID: PMC4116414          DOI: 10.1152/ajpheart.00694.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  56 in total

1.  Differences in action potential and early afterdepolarization properties in LQT2 and LQT3 models of long QT syndrome.

Authors:  C R Studenik; Z Zhou; C T January
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Repolarizing currents in ventricular myocytes from young patients with tetralogy of Fallot.

Authors:  P Schaffer; B Pelzmann; E Bernhart; P Lang; H Mächler; B Rigler; B Koidl
Journal:  Cardiovasc Res       Date:  1999-08-01       Impact factor: 10.787

3.  Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype.

Authors:  Mari Pekkanen-Mattila; Hugh Chapman; Erja Kerkelä; Riitta Suuronen; Heli Skottman; Ari-Pekka Koivisto; Katriina Aalto-Setälä
Journal:  Exp Biol Med (Maywood)       Date:  2010-04

4.  The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes.

Authors:  Shengde Peng; Antonio E Lacerda; Glenn E Kirsch; Arthur M Brown; Andrew Bruening-Wright
Journal:  J Pharmacol Toxicol Methods       Date:  2010-02-11       Impact factor: 1.950

5.  Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels.

Authors:  I C Yang; M W Scherz; A Bahinski; P B Bennett; K T Murray
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

Review 6.  Opportunities for use of human iPS cells in predictive toxicology.

Authors:  B D Anson; K L Kolaja; T J Kamp
Journal:  Clin Pharmacol Ther       Date:  2011-03-23       Impact factor: 6.875

7.  Contributions of ion channel currents to ventricular action potential changes and induction of early afterdepolarizations during acute hypoxia.

Authors:  Namit Gaur; Yoram Rudy; Livia Hool
Journal:  Circ Res       Date:  2009-10-29       Impact factor: 17.367

8.  Functional cardiomyocytes derived from human induced pluripotent stem cells.

Authors:  Jianhua Zhang; Gisela F Wilson; Andrew G Soerens; Chad H Koonce; Junying Yu; Sean P Palecek; James A Thomson; Timothy J Kamp
Journal:  Circ Res       Date:  2009-02-12       Impact factor: 17.367

9.  Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes.

Authors:  Feng Cao; Roger A Wagner; Kitchener D Wilson; Xiaoyan Xie; Ji-Dong Fu; Micha Drukker; Andrew Lee; Ronald A Li; Sanjiv S Gambhir; Irving L Weissman; Robert C Robbins; Joseph C Wu
Journal:  PLoS One       Date:  2008-10-22       Impact factor: 3.240

10.  Local control of excitation-contraction coupling in human embryonic stem cell-derived cardiomyocytes.

Authors:  Wei-Zhong Zhu; Luis F Santana; Michael A Laflamme
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more
  286 in total

1.  Determination of the human cardiomyocyte mRNA and miRNA differentiation network by fine-scale profiling.

Authors:  Joshua E Babiarz; Morgane Ravon; Sriram Sridhar; Palanikumar Ravindran; Brad Swanson; Hans Bitter; Thomas Weiser; Eric Chiao; Ulrich Certa; Kyle L Kolaja
Journal:  Stem Cells Dev       Date:  2012-01-04       Impact factor: 3.272

Review 2.  Human induced pluripotent stem cells--from mechanisms to clinical applications.

Authors:  Katharina Drews; Justyna Jozefczuk; Alessandro Prigione; James Adjaye
Journal:  J Mol Med (Berl)       Date:  2012-05-30       Impact factor: 4.599

Review 3.  Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.

Authors:  Evangeline Tzatzalos; Oscar J Abilez; Praveen Shukla; Joseph C Wu
Journal:  Adv Drug Deliv Rev       Date:  2015-09-30       Impact factor: 15.470

4.  Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.

Authors:  Liang Guo; Sandy Eldridge; Mike Furniss; Jodie Mussio; Myrtle Davis
Journal:  Curr Protoc Chem Biol       Date:  2015-09-01

5.  Rigorous Phenotyping of Cardiac iPSC Preparations Requires Knowledge of Their Resting Potential(s).

Authors:  Wayne R Giles; Denis Noble
Journal:  Biophys J       Date:  2016-01-05       Impact factor: 4.033

Review 6.  Induced pluripotent stem cells: the new patient?

Authors:  Milena Bellin; Maria C Marchetto; Fred H Gage; Christine L Mummery
Journal:  Nat Rev Mol Cell Biol       Date:  2012-10-04       Impact factor: 94.444

Review 7.  Challenges for stem cells to functionally repair the damaged auditory nerve.

Authors:  Karina Needham; Ricki L Minter; Robert K Shepherd; Bryony A Nayagam
Journal:  Expert Opin Biol Ther       Date:  2012-10-25       Impact factor: 4.388

8.  Dual optical recordings for action potentials and calcium handling in induced pluripotent stem cell models of cardiac arrhythmias using genetically encoded fluorescent indicators.

Authors:  LouJin Song; Daniel W Awari; Elizabeth Y Han; Eugenia Uche-Anya; Seon-Hye E Park; Yoko A Yabe; Wendy K Chung; Masayuki Yazawa
Journal:  Stem Cells Transl Med       Date:  2015-03-13       Impact factor: 6.940

9.  Myosin light chain 2-based selection of human iPSC-derived early ventricular cardiac myocytes.

Authors:  Alexandra Bizy; Guadalupe Guerrero-Serna; Bin Hu; Daniela Ponce-Balbuena; B Cicero Willis; Manuel Zarzoso; Rafael J Ramirez; Michelle F Sener; Lakshmi V Mundada; Matthew Klos; Eric J Devaney; Karen L Vikstrom; Todd J Herron; José Jalife
Journal:  Stem Cell Res       Date:  2013-09-18       Impact factor: 2.020

10.  Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.

Authors:  Oksana Sirenko; Evan F Cromwell; Carole Crittenden; Jessica A Wignall; Fred A Wright; Ivan Rusyn
Journal:  Toxicol Appl Pharmacol       Date:  2013-10-01       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.